Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will participate in a fireside chat at the 35th Annual Roth Conference scheduled for March 12-14, 2023 to be held at The Ritz Carlton, Laguna Niguel in Dana Point, California.
Details regarding Revelation fireside chat are as follows:
35th Annual Roth Conference Presentation Details
Date: |
Tuesday, March 14, 2023 |
Time: |
12:30 p.m. Pacific Time |
Location: |
Healthcare - Salon 5 @ The Ritz Carlton, Laguna Niguel |
Webcast: |
REVB Webcast Link |
A live webcast of the presentation will also be available in the Investor Relations section of Revelation’s website at https://www.revbiosciences.com. A replay of the presentation will be available on Revelation’s website for 30 days following the event.
Mr. Rolke will be available for one-on-one meetings throughout the conference in person and virtually.
About Revelation Biosciences Inc.
Revelation Biosciences, Inc. is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that are based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. REVTx‑100 is being developed as a prevention and treatment of infection. REVTx‑200 is being developed as an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx‑300 is being developed as a potential therapy for the treatment of acute and chronic organ disease including AKI, CKD, myocarditis, and NASH. REVTx‑99b is being developed as a treatment for food allergies. REVDx‑501 is being developed as a rapid diagnostic that can be used to detect IP-10 as a surrogate biomarker for any type of respiratory infection, eliminating the need for specialized instrumentation.
For more information on Revelation, please visit www.RevBiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005202/en/
Contacts
Sandra Vedrick
Vice President, Investor Relations & Human Resources
Revelation Biosciences Inc.
Email: svedrick@revbiosciences.com
and
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
